EC approval decision anticipated in second quarter of 2025
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Seeking Alpha / 1 hour from now 1 Views
EC approval decision anticipated in second quarter of 2025
Comments